TG Therapeutics Inc (TGTX)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 25,583 | 13,062 | -198,335 | -348,101 | -279,381 |
| Revenue | US$ in thousands | 324,397 | 221,047 | 2,785 | 6,689 | 152 |
| Pretax margin | 7.89% | 5.91% | -7,121.54% | -5,204.08% | -183,803.29% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $25,583K ÷ $324,397K
= 7.89%
TG Therapeutics Inc's pretax margin has shown significant improvement over the years, transitioning from negative figures in 2020, 2021, and 2022 to positive values in 2023 and 2024. The company experienced a drastic improvement in its performance, rebounding from a pretax margin of -183,803.29% in 2020 to reach 5.91% in 2023, signaling a major turnaround in its profitability. In 2024, the positive trend continued with a pretax margin of 7.89%, indicating the company's ability to effectively manage its expenses and generate higher earnings before taxes despite challenges it faced in the past. The positive pretax margins in 2023 and 2024 suggest that TG Therapeutics Inc is moving towards sustainable profitability, showcasing its potential for growth and financial stability.
Peer comparison
Dec 31, 2024